about
Psoriasis: symptoms, treatments and its impact on quality of lifeUstekinumab: an evidence-based review of its effectiveness in the treatment of psoriasisDevelopment of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP).Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists.An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial.Risk of cardiovascular disorders in psoriasis patients: current and future.Efficacy, Safety, and Out-of-pocket Costs are the Most Important Factors to Patients in Choosing a Psoriasis Therapy.A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation.Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis (the Practice Study).Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients.Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.Non-adherence to topical treatments for actinic keratosis.Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ).Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units.Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action.Personalizing dermatology: the future of genomic expression profiling to individualize dermatologic therapy.Maximizing patient adherence for optimal outcomes in psoriasis.Adherence to topical treatment in psoriasis: a systematic literature review.Topical drug delivery systems in dermatology: a review of patient adherence issues.Factors contributing to poor treatment outcomes in childhood atopic dermatitis.Once-daily luliconazole cream 1% for the treatment of interdigital tinea pedis.Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy.Clinical studies in dermatology require a post-treatment observation phase to define the impact of the intervention on the natural history of the complaint.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.Adherence to Topical Therapies for the Treatment of Psoriasis: Surveys of Physicians and Patients.Medication use and associated health care outcomes and costs for patients with psoriasis in the United States.What is new in topical therapy for psoriasis?A novel formulation of mometasone furoate in psoriasis patients: a multicenter, randomized, double-blind clinical study.Potential barriers to adherence in pediatric dermatology.Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities.Topical therapy of psoriasis: Where do we stand?The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis.Effectiveness of the Healthy Skin Clinic--a randomized clinical trial of nurse-led patient counselling in hand eczema.Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study.Every dermatology consultation: think adherence.Patients' views of nurse prescribing: effects on care, concordance and medicine taking.
P2860
Q22306121-B972DCFC-EDB8-434B-9FCD-D9451F75F294Q34041797-0F223BE4-A57B-42F3-AE1C-1CDF8DA33E01Q34071609-F96468F8-AA5D-4BCD-84A8-32B1F073DF86Q34237346-D7B51FBD-EB69-4F1D-A71A-E149F266FEE5Q34282434-4E14AE73-8A83-46E0-8171-80C6E1002561Q34323212-D8CF9BCA-D15C-4451-ABA5-432E3BD78D75Q34846987-3D2CA7FA-87AA-4D05-94A6-AFA1F5466E83Q35120210-9E3BE631-AE9D-44E2-A6F8-DA7C6FDC4120Q36247035-F985BC32-6418-4121-992A-469FDA8EC8B9Q36640532-162314A1-840A-4438-B312-9CB4D3CE8055Q37150168-BACF8348-6037-4D24-ABEC-0999C3B2BDA1Q37257450-7CC883B0-45EA-4C08-8D8C-9136E414AC7EQ37344587-21078888-B65A-4F93-B926-88E3A59DD753Q37412640-5E43EBED-4EDA-4A50-AB06-653A488F9E70Q37638892-571CF0FD-6D9B-4077-BA0C-1326A97C6C02Q37693752-2AF3A016-2E83-4A9D-86E5-60C6615EE162Q37735794-05DCFA19-01C9-4B72-B980-967AF30BA3A5Q37831326-1240A9BE-CFD5-4C9C-8C6F-2E09D5D2494CQ37867174-9A4FFFF8-6FE1-4DB3-9E08-52ACD07B893CQ38003487-4C8A0921-BCEC-414F-910E-7B0AE18A8252Q38031916-382E2A8D-8E98-46D1-BEE1-46D7A9E3C1B9Q38394059-4FA24B8D-C3AE-45DE-9A24-810849B5CF80Q38630778-4E6E5057-CF3F-40C4-BBD4-067E1A25BB11Q38635555-DA7C3A89-2F64-42D0-8C09-F468A5B6A343Q38792733-DDFD652A-B1C3-4C82-A4D9-9F7E45B5AC3AQ38831055-7453D2FC-7AEA-4BE2-B5CE-52DE889B1DBAQ39248590-E04EBAAF-14E4-4A54-BFFA-6B921ECF722FQ42073146-86C37355-804C-4448-8CCD-B6D5C81AA687Q44175157-BB9CDBFE-1C11-4617-824A-9DCFCE59C9ABQ44191089-3B78A2BE-A8B5-4F0C-958A-13D136E37BAAQ44734250-5A787C7B-7753-4E12-904D-9EC08785C9D6Q44966161-655F74CE-4208-49C6-BD55-C0D9D70F8353Q45636613-C3D66B77-B953-4BFF-8403-2F970DF7FEA4Q46703507-28C37A88-411D-40CC-8CFA-75FCF2385971Q47132615-C0335175-9536-4A95-A722-8DB3A6E3C584Q48007058-70D9094B-0430-4032-8EC3-DAAF4FDC2368Q48078308-5CBFEB15-45CE-4A0A-82CD-F4342731356DQ48085635-30F3814D-ABAD-4E24-A274-D062940F339EQ48117121-35822522-2F86-48E8-A89A-7D754F8A62ADQ48173552-C3AAB767-A7AF-4B21-975A-13C5B7E19BA3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Psoriasis: improving adherence to topical therapy.
@en
Psoriasis: improving adherence to topical therapy.
@nl
type
label
Psoriasis: improving adherence to topical therapy.
@en
Psoriasis: improving adherence to topical therapy.
@nl
prefLabel
Psoriasis: improving adherence to topical therapy.
@en
Psoriasis: improving adherence to topical therapy.
@nl
P2093
P1476
Psoriasis: improving adherence to topical therapy
@en
P2093
Alan Menter
Elizabeth J Horn
International Psoriasis Council
Mohammad K Basra
Peter C M van de Kerkhof
Rajesh Balkrishnan
P304
P356
10.1016/J.JAAD.2008.08.028
P407
P577
2008-10-02T00:00:00Z